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Abstract 1 
Background 2 
Therapeutic radiotherapy is an important treatment for pelvic cancers. Historically, low 3 
fiber diets have been recommended despite a lack of evidence and potentially beneficial 4 
mechanisms of fiber.  5 
Objective 6 
This randomized controlled trial compared low, habitual and high fiber diets for the 7 
prevention of gastrointestinal toxicity in patients undergoing pelvic radiotherapy.   8 
Design   9 
Patients were randomized to low fiber (≤10 g/d non-starch polysaccharide ‘NSP’), 10 
habitual (control) or high fiber (≥18 g/d) diets and received individualized counseling at 11 
the start of radiotherapy to achieve these targets. The primary end point was the 12 
difference between groups in the change in the Inflammatory Bowel Disease 13 
Questionnaire - Bowel Subset (IBDQ-B) score between start and nadir (worst) score 14 
during treatment. Other measures included macronutrient intake, stool diaries and fecal 15 
short-chain fatty acids (SCFA).   16 
Results 17 
Patients were randomized to low (n=55), habitual (n=55) or high fiber (n=56) dietary 18 
advice. Fiber intakes were significantly different between groups (p<0.001). The 19 
difference between groups in the change in IBDQ-B scores between start and nadir was 20 
not significant (p=0.093). However, the change in score between start and end of 21 
radiotherapy was smaller in the high fiber group (mean -3.7, SD ± 12.8) compared with 22 
the habitual fiber group (-10.8, SD ± 13.5, p=0.011). At 1-year post-RT (n=126) the 23 
difference in IBDQ-B scores between the high fiber (+0.1 ± 14.5) and the habitual fiber 24 
(-8.4 ± 13.3) groups was significant (p=0.004). No significant differences were 25 
observed in stool frequency, form or SCFA concentrations. Significant reductions in 26 
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energy, protein and fat intake occurred in the low and habitual fiber groups only. 27 
       28 
Conclusions    29 
Dietary advice to follow a high fiber diet during pelvic radiotherapy resulted in reduced 30 
gastrointestinal toxicity both acutely and at one year compared with habitual fiber 31 
intake. Restrictive, non-evidence based advice to reduce fiber intake in this setting 32 
should be abandoned.  33 
 34 
Key words: gastrointestinal, toxicity, radiotherapy, pelvic, cancer, pelvic radiation 35 
disease, fiber, fibre, non-starch polysaccharide, NSP, short chain fatty acids, SCFA, 36 
Inflammatory Bowel Disease Questionnaire, IBDQ, IBDQ-B 37 
      38 
  39 
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Introduction 40 
Radiation therapy is used in at least 50% of cancer patients and plays a critical role in 41 
25% of cancer cures. It is estimated that in the US, approximately 300,000 patients per 42 
annum receive radiotherapy for pelvic or abdominal malignancies (1, 2). In the UK, an 43 
estimated 17,000 patients receive radical (curative) radiotherapy per annum (3). Despite 44 
major advances in radiotherapy techniques, radiation-induced gastrointestinal toxicity is 45 
common. Acutely (during treatment), 90% of patients experience changes in bowel 46 
habit (4). Delayed intestinal radiation toxicity is a progressive condition with few 47 
therapeutic options and substantial long-term morbidity and mortality (5). Currently 48 
there are an estimated 1.6 million Americans living with post-radiation intestinal 49 
dysfunction (1). Modern innovation in radiation technique may reduce the severity of 50 
acute and chronic toxicity but it is unlikely ever to abolish it completely.  51 
 52 
Therapeutic strategies for the prevention of radiation-induced gastrointestinal toxicity 53 
are limited. The free radical scavenger, amifostine is the only FDA-approved agent but 54 
concerns remain regarding its side-effects and its potentially tumour-protective 55 
properties (1). Dietary strategies have been trialed primarily as prophylactic agents but 56 
with limited success (6), although lack of evidence may be partly explained by the poor 57 
quality of many studies and the acknowledged difficulties of undertaking robust, 58 
placebo-controlled dietary interventions (7). Clinical benefit for the manipulation of 59 
dietary fiber is inconclusive. Four randomized controlled trials have been conducted 60 
recruiting 264 patients in total (8-11). Three used fiber supplements in combination with 61 
low fat or low lactose diets (8, 9, 11) whilst another used a low fiber diet in combination 62 
with a low lactose diet (10) thus limiting the conclusions that could be drawn.  63 
 64 
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Anecdotal evidence suggests many patients are advised to reduce fiber intake during 65 
pelvic radiotherapy. However, high fiber intake may be beneficial via multiple 66 
mechanisms. Fermentable (soluble) fiber provides a substrate for the production of 67 
short-chain fatty acids (SCFA) with beneficial effects on gut health (12) such as 68 
promotion of sodium and associated water uptake and anti-inflammatory activity (13). 69 
The gastrointestinal mucosal response to radiation is pro-inflammatory (14) with 70 
pathological parallels to inflammatory bowel disease (15), where high fiber 71 
interventions have been shown to be effective (16). 72 
  73 
This randomized controlled trial was designed to test the hypothesis that a high fiber 74 
diet would prevent or reduce acute and chronic radiation-induced gastrointestinal 75 
toxicity in patients undergoing radiotherapy for pelvic cancers. Its secondary objectives 76 
were to examine clinical outcomes of importance to patients including quality of life, 77 
impact on stool frequency and form (consistency) and nutritional intake.  78 
79 
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Subjects and Methods  80 
This two-center, three-arm (low fiber, habitual fiber, high fiber), randomized controlled 81 
trial (US NIH Trial ID: NCT 01170299) was conducted in compliance with CONSORT 82 
recommendations (17). It was approved by the institutional committees for clinical 83 
research and ethical consent was granted by the local Research Ethics Committee.   84 
 85 
Patients and radiotherapy protocols 86 
Patients were recruited from the Royal Marsden NHS Foundation Trust, Sutton, Surrey 87 
and London and from the Royal Surrey County Hospital, Guildford, Surrey. Eligible 88 
patients were those with histologically proven gynecological or lower gastrointestinal 89 
cancer, due to receive radical (curative) radiotherapy to the pelvis, with or without 90 
concomitant chemotherapy and able to tolerate 100% oral diet. Those with established 91 
wheat intolerance or celiac disease, a gastrointestinal stent, a gastrointestinal stoma or 92 
enrolled in other trials with conflicting toxicity end-points were excluded. 93 
 94 
Radiotherapy treatment (all pelvic sites) was delivered using using External Beam 95 
(EBRT) or Intensity Modulated (IMRT) radiotherapy techniques (Supplemental Table 96 
1). All patients received at least 45 Gray (Gy) to the pelvis in 1.8 Gy daily fractions, 5 97 
times per week, over 5 to 7 weeks. Patients with gynecological cancers received high or 98 
low dose adjuvant brachytherapy where indicated. Concomitant chemotherapy 99 
comprised oral daily capcitabine, mitomycin C in combination with oral capcitabine and 100 
weekly IV cisplatin for colorectal, anal and cervical cancers respectively.     101 
 102 
Trial design  103 
Informed signed consent was obtained prior to any study related procedures. Following 104 
collection of baseline data, patients were allocated to study group using the 105 
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minimization method, by the Institute of Cancer Research Randomization Unit, 106 
stratified by pelvic site and receipt of concomitant chemotherapy. The three study 107 
groups comprised: [1] low fiber diet (non-starch polysaccharide, NSP, target ≤10 g/d); 108 
[2] habitual or ad-libitum diet (control group); [3] high fiber diet (NSP, target ≥18 g/d). 109 
Patients and investigators were unblinded to intervention. 110 
 111 
Patients in all study groups received an enrollment (start of treatment) and exit (end of 112 
treatment) interview with the study dietician and a minimum of two on-treatment 113 
interviews, each of 20 – 30 minutes duration during their radiotherapy. Interviews were 114 
designed to allow for collection of study outcome measurements and to review 115 
compliance with treatment allocation (i.e. fiber targets). At the enrollment interview, 116 
patients allocated to the high or low fiber groups were given a daily fiber target and 117 
counseled on how to achieve this target. The intervention was based entirely on dietary 118 
manipulation with fiber supplements neither provided nor recommended. Counseling to 119 
achieve the required dietary fiber targets comprised an individualized discussion 120 
regarding usual food choices, with emphasis on fiber-rich foods and an agreement as to 121 
how to adjust these choices to achieve prescribed target. In addition, patients were given 122 
educational / recording items including a ‘Fiber in Foods’ booklet specifically designed 123 
for the trial detailing the fiber content in ‘points’ (or exchanges) of over 400 foods 124 
commonly consumed in the UK and an Exchange Diary in which to track their fiber 125 
intake to improve understanding, motivation and compliance. In contrast, patients in the 126 
habitual fiber (control) group were counseled at their enrollment interview to maintain 127 
their normal diet throughout radiotherapy treatment and not to adjust their fiber intake. 128 
However they still had the same number of study visits and access to the research team, 129 
although educational or recording materials were not provided to this group. Patients in 130 
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all groups had access to the research dietician throughout the study to answer ad hoc 131 
study-related dietary or nutritional queries. The duration of each face-to-face interview 132 
during the study was recorded and median contact time per interview compared between 133 
study groups.      134 
 135 
Outcome measurements 136 
Gastrointestinal toxicity was assessed as severity of bowel symptoms experienced 137 
during the acute (baseline to 5-7 weeks) and chronic (1 year following completion of 138 
radiotherapy) period. Symptoms were assessed using the Inflammatory Bowel Disease 139 
questionnaire – bowel subset (IBDQ-B) which has been validated in the radiotherapy 140 
setting (4). The 32-question IBDQ is a quality of life instrument originally developed 141 
for patients with Inflammatory Bowel Disease (18). A maximum score of 224 and 142 
minimum of 32 can be obtained with lower scores indicating most severe symptoms. 143 
The 10-question (embedded) IBDQ-B has a maximum score of 70 and minimum of 10, 144 
once again lower scores indicative of more severe symptoms.  145 
 146 
The IBDQ and IBDQ-B scores were obtained at baseline, immediately prior to 147 
commencing radiotherapy and thereafter weekly during the 5-7 weeks of radiotherapy 148 
and one year after delivery of last radiotherapy session. Data was analyzed as absolute 149 
values for nadir (worst) score, end of radiotherapy (acute) and one year after the final 150 
radiotherapy (chronic), as well as change in values from baseline to each of these time-151 
points. Total acute bowel symptom burden, as a predictor of chronic burden (19) was 152 
examined by computing IBDQ-B area under the curve (AUC) in patients with at least 4 153 
consecutive acute scores. The primary outcome was the difference between study 154 
groups in the change in IBDQ-B between baseline and nadir score during radiotherapy.   155 
 156 
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Other gastrointestinal outcomes included stool form (consistency) and frequency 157 
(output). Patients were instructed in the completion of daily self-reported stool diaries 158 
which included the Bristol Stool Form Scale (20) for the assessment of stool form, 159 
starting on the day following their enrollment interview through to their exit interview 160 
covering their entire radiotherapy treatment period. Mean weekly stool frequency, stool 161 
form, number of days on which stools of type 6/7 were passed and number of days on 162 
which anti-diarrheal medication was used were compared between groups during week 163 
1, week 4 and the final week of radiotherapy.   164 
 165 
Stool SCFA concentrations were measured, to investigate the effect of fiber intake on 166 
these, and to explore whether they may be protective mechanisms in preventing 167 
radiation-induced gastrointestinal toxicity. Stool samples were collected from patients 168 
on day 1 and final day of radiotherapy and immediately weighed and stored at -80°C for 169 
future analysis of SCFA using gas liquid chromatography. Briefly, SCFA were 170 
extracted in a 1:4 dilution of extraction buffer (1% H2PO4, 0.1% HgCl2) containing an 171 
internal standard (2,2-dimethylbutyric acid) and homogenized (Seward Stomacher 80). 172 
The extraction was centrifuged (Beckman GS6R) at 5000g for 20 minutes and the 173 
supernatant passed through a 0.2 μm filter. In duplicate, filtered supernatant were 174 
injected splitless into a gas liquid chromatography system and analyzed using a 175 
chromatogram database (Aligent Technologies, US) to give concentrations of acetic, 176 
propionic, butyric, valeric, isobutyric and isovaleric acids in μmol/g wet stool.  177 
 178 
All patients completed a 7-day food diary during their first and final week of 179 
radiotherapy, prospectively recording all food and fluid consumption. Data was entered 180 
into a food composition database (Dietplan v.6 Forestfield Software Ltd., Horsham, 181 
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Surrey). Fiber intake was recorded as NSP intake per day and absolute and change 182 
values were calculated and compared. Compliance with fiber target was defined as 183 
achieving 80% of the target for that group, equating to <12.0 g/d NSP for the low fiber 184 
group (target ≤10 g/d); a change of <20% in NSP intake between first and final week for 185 
the habitual fiber group and >14.4 g/d NSP for the high fiber group (target ≥18 g/d). 186 
Body weight and Body Mass Index (BMI) were obtained at baseline and end of 187 
radiotherapy and absolute and change values were compared between groups.  188 
 189 
Palatability of the intervention diets was assessed at the end of radiotherapy using a 150 190 
mm visual analogue scale with responses ranging from 0mm ‘much worse than my 191 
normal diet’; 75mm ‘no different to my normal diet’; 150mm ‘much better than my 192 
normal diet’. Impact of following the intervention diets on cost of weekly food bills, 193 
time spent shopping and in food preparation was assessed by the study research 194 
dietician at the exit interview and is reported descriptively. Participants were also asked 195 
at each study visit to recall any costs they had incurred that were directly related to 196 
symptom management (e.g. purchase of incontinence pads).   197 
 198 
Statistical methods 199 
Statistical analysis was performed using SPSS software (v.21) employing the ANOVA 200 
method for normally distributed data (e.g. IBDQ-B, total IBDQ scores) or Kruskal 201 
Wallis test for non-normally distributed data (e.g. stool frequency) between the three 202 
groups. Where significant, intergroup comparisons were compared using a Bonferroni 203 
post hoc correction. The primary end-point was defined as the change in IBDQ-B score 204 
between start of radiotherapy and nadir score during the radiotherapy period (acute). 205 
This was analyzed by intention to treat (ITT) and per protocol methods. For ITT 206 
analysis, missing baseline scores were imputed by carrying backward the first available 207 
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score, and missing scores at the end of radiotherapy or one year were imputed using last 208 
value carried forward. Missing scores during treatment were imputed by taking an 209 
average of scores either side of those missing. Data from patients who withdrew from 210 
the trial before commencing the intervention was excluded from the analysis. Data from 211 
patients who withdrew during the intervention but consented to allow their data to be 212 
included was included in the ITT analysis. Per protocol analysis was performed using 213 
scores from patients who achieved ≥80% compliance with fiber target, assessed from 214 
the 7-day food diary for the last week of treatment. Results of these analyses were 215 
considered significant if p<0.05 (ANOVA) in which case post-hoc analysis was 216 
undertaken.  217 
 218 
The sample size calculation was based on a previous nutrition intervention study with a 219 
similar design employing the IBDQ-B as the primary end-point (21). It was calculated 220 
that 156 patients were required (52 per group) to detect a difference in the change in 221 
IBDQ-B score of ≥6 points between groups from start of radiotherapy to nadir score 222 
during treatment, with a significance level of 0.02 (allowing for multiple comparisons) 223 
and power of 90%.  224 
  225 
 226 
227 
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Results  228 
Patients 229 
Recruitment took place between December 2009 and December 2013 and was closed 230 
when accrual reached n=166, with 10 additional patients recruited to allow for 231 
withdrawals. The final trial measurement (1 year follow-up) was obtained in January 232 
2015. Figure 1 outlines study accrual. Of the 583 eligible patients, 417 declined 233 
representing a recruitment rate of 28%. The major reason for declining study enrollment 234 
was reluctance to adopt a possible change in diet (36% of patients).  235 
 236 
Seven patients withdrew: two declined to commence the study immediately following 237 
randomization (low fiber group); two had a stoma placed before radiotherapy (habitual 238 
fiber: 1, high fiber: 1); two were hospitalized during treatment and requested withdrawal 239 
(habitual fiber: 1, low fiber: 1) and one had a change in treatment plan and did not 240 
receive radiotherapy (high fiber). A total of 161 patients comprised the ITT population 241 
as follows: completed the intervention (n=159); withdrew part-way through the study 242 
but consented to their data being included (n=2). Four adverse events occurred all of 243 
which were hospital admission for symptom control. None of these were considered 244 
related in any way to the study intervention. There were no significant differences in 245 
baseline characteristics between groups (Table 1).  246 
 247 
A total of 644 face-to-face interviews with patients were conducted by the study 248 
dietician. Median contact time per interview was not significantly different between 249 
groups (p=0.161) and amounted to: 16 minutes for the habitual fiber group (min: 11, 250 
max: 36), 18 minutes (min: 9, max: 31) for the low fiber group and 18 minutes (min: 10, 251 
max: 34 mins) for the high fiber group.  252 
 253 
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Inflammatory Bowel Disease Questionnaire – Bowel subset 254 
IBDQ-B scores were obtained weekly for all patients. The number of missing scores, 255 
requiring imputation, for weeks 1 to 6 and one year post-RT was: 1, 5, 7, 10, 17, 9 and 256 
35 respectively. Raw scores and comparisons between groups at all time points are 257 
shown in Table 2. There were no differences in IBDQ-B scores at baseline between the 258 
three groups. Overall, IBDQ-B scores decreased in all groups during treatment, 259 
indicative of worsening bowel symptoms. In the ITT population, there was no 260 
significant difference between groups in the change in score between baseline (start of 261 
radiotherapy) and nadir score during treatment (primary endpoint, p=0.093).  262 
 263 
There was no differences in absolute IBDQ-B scores at the end of radiotherapy between 264 
the three groups, however, there was a significant difference in the between group 265 
change in scores between baseline and final week of radiotherapy (p=0.014) (Table 2). 266 
Post hoc analysis revealed a smaller reduction in score in the high fiber group (-3.7, SD 267 
12.8) compared with the habitual fiber group (-10.8, SD 13.5), a clinically significant 268 
difference of -7.1 points (95% CI -12.99, -1.27) (p=0.011). However, the change in 269 
score was not significantly different between the low fiber group (-7.9, SD 11.3) and 270 
habitual fiber group (p=0.711) or between the low fiber and high fiber groups 271 
(p=0.251). 272 
 273 
The absolute IBDQ-B scores at 1 year post-RT and the change in scores between 274 
baseline and 1 year post-RT were significantly different between groups (Table 2). Post 275 
hoc analysis revealed that at 1 year following radiotherapy, IBDQ-B scores had returned 276 
to baseline values in the high fiber group (+0.1, SD 14.5) compared with a reduction in 277 
the habitual fiber group (-8.4, SD 13.3), a clinically significant difference of -8.5 points 278 
(95% CI -14.8, -2.2) (p=0.004). However, the change in IBDQ-B scores was not 279 
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significantly different between the low fiber group (-4.9, SD 12.7) and habitual fiber 280 
group (p=0.546) or between the low fiber and high fiber groups (p=0.172) (Table 2).  281 
 282 
Per protocol analysis revealed no significance differences between groups in IBDQ-B 283 
scores at any time-points or in the change in scores between time-points. However, 284 
patient numbers were small with only 128 patients (34 low fiber, 22 habitual, 27 high 285 
fiber) included in the analysis due to limited numbers achieving ≥80% compliance with 286 
fiber target.  287 
 288 
Computation of IBDQ-B area under the curve (153 patients) showed no significant 289 
difference between groups (p=0.576; Kruskal Wallis test, non-parametric data). 290 
 291 
 292 
Inflammatory Bowel Disease Questionnaire 293 
IBDQ scores were obtained weekly for all patients with missing scores imputed as 294 
reported above for IBDQ-B. Raw scores and comparisons between groups at all time 295 
points are shown in Table 2. There were no differences in IBDQ scores at baseline 296 
between the three groups. Overall, scores decreased in all groups during treatment, 297 
indicative of worsening overall symptoms and resulting impaired quality of life. In the 298 
ITT population, there was no significant difference between groups in the change in 299 
score between baseline (start of radiotherapy) and nadir score during treatment 300 
(p=0.203).  301 
 302 
There was no difference in absolute IBDQ scores at the end of radiotherapy between the 303 
three groups, however, there was a significant difference in the change in score between 304 
baseline and final week of radiotherapy (p=0.018). Post hoc analysis revealed a smaller 305 
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reduction in score in the high fiber group (-8.2, SD 30.2) compared with the habitual 306 
fiber group (-24.5, SD 32.0), a clinically significant difference of -16.2 points (95% CI -307 
30.12, -2.46) (p=0.015). However, the change in score was not significantly different 308 
between the low fiber group and habitual groups (p=0.708) nor between the low fiber 309 
and high fiber groups (p=0.303). 310 
 311 
The absolute IBDQ scores at 1 year post-RT (p=0.001) and the change in scores 312 
between baseline and 1 year post-RT were significantly different between groups 313 
(p<0.001). Post hoc analysis revealed that at 1 year following radiotherapy, IBDQ 314 
scores had returned to exceed baseline values marginally in the high fiber group (+2.1, 315 
SD 29.4) compared with a reduction in the habitual fiber group (-21.4, SD 33.0), a 316 
difference of -23.8 points (95% CI -38.2, -9.3) (p<0.001). The change in IBDQ scores 317 
was also significantly different between the low (-13.23, SD 30.3) and high fiber groups 318 
(p=0.030) but not between the low fiber and habitual fiber groups (p=0.530) (Table 2).  319 
 320 
Per protocol analysis (n=34 low fiber, n=22 habitual, n=27 high fiber) revealed a 321 
significant difference between groups in IBDQ scores at 1 year post-RT (p=0.030). Post 322 
hoc analysis revealed a significant difference of 20.4 points (95% CI 1.9, 38.9) 323 
(p=0.026) between the high fiber and habitual fiber groups. However, there were no 324 
differences between groups in the change in IBDQ score between any time-points.    325 
 326 
Stool frequency and form  327 
Stool diaries were returned by 125 (78%) patients, (39/53 low fiber; 44/54 habitual fiber 328 
group; 42/54 high fiber). There were no significant differences in stool frequency or 329 
stool form during week 1 (start of radiotherapy) or the final week (end of radiotherapy) 330 
between any of the three groups, nor was there a difference in the number of days 331 
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during which patients experienced a stool form of 6 or 7 (loose or watery stools) or the 332 
number of days on which anti-diarrheal medication was taken (Table 3).  333 
 334 
Short-chain fatty acids 335 
In an exploratory analysis, paired stool samples were provided by a sub-group of  41 336 
patients at baseline and end-RT (low fiber: 15, habitual fiber group: 16, high fiber: 10). 337 
No significant differences were found between groups in total SCFA concentrations 338 
either at baseline or end-RT (Supplemental Table 2).     339 
 340 
Nutritional data 341 
The number of 7-day food diaries returned was 146 (91%) at baseline (47 low fiber 342 
group, 51 habitual fiber, 48 high fiber) and 139 (86%) during the final week of RT (41 343 
low fiber group, 44 habitual fiber, 43 high fiber). During week 1 of radiotherapy, 344 
following dietary advice, there was a significant difference in fiber intake between 345 
groups (p<0.001: ANOVA) which was also apparent during the final week of 346 
radiotherapy (p<0.001: ANOVA), all in line with group allocations (low fiber < habitual 347 
fiber < high fiber) (Table 4). There were no differences between groups in the intake of 348 
fat or carbohydrates during week 1, final week of radiotherapy or change between week 349 
1 and final week. However, there was a significant difference in protein intake (g/d) 350 
between groups (p=0.012) during the final week of radiotherapy (Table 4). Post hoc 351 
analysis revealed a mean difference of 14.6 g/day between the low and high fiber 352 
groups (68.6, SD 24.5 vs 78.4, SD 22.7, p=0.011).   353 
 354 
Using paired data (food diaries returned at both time-points) significant within-group 355 
reductions in the low and habitual fiber groups were seen in total energy (low fiber: -356 
146 kcals / d, habitual fiber -171, p=0.019 and 0.010 respectively); protein (low fiber: -357 
8.5 g / d, habitual fiber -7.7, p=0.002 and 0.006 respectively) and fat (low fiber: -7.5 g / 358 
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d, habitual fiber -8.3, p=0.014 and 0.016 respectively) intake between week 1 and final 359 
week of radiotherapy. In contrast no significant differences in nutrient intake were 360 
observed in the high fiber group.  361 
 362 
There were no significant differences in body weight or BMI at either baseline or end of 363 
RT. (Table 4). Difference in the change in BMI between groups was significant. Post 364 
hoc analysis revealed this to be between the low and habitual fiber groups (p=0.058).    365 
   366 
Of the 40/53 (75%) patients in the low fiber group and 38/54 (70%) in the high fiber 367 
group who completed the palatability questionnaires, there was no significant difference 368 
in perceived palatability of the low (median 78.5 (min 7 – max 146) mm) vs high fiber 369 
diets (78.0 (5 – 150)). 370 
 371 
There was little difference between the high and low fiber groups with respect to the 372 
impact of the study diet. A total of 64% of patients in the low fiber vs 59% in the high 373 
fiber group reported that the study diet had a minimal effect, or had reduced the cost of 374 
their weekly food bills; 60% of patients in the low fiber group vs 58% in the high fiber 375 
group reported that the study diet had no impact, or reduced time spent shopping and 376 
64% of patients in the low fiber vs 56% in the high fiber group reported that the study 377 
diet had no effect, or had reduced food preparation time. No response: 27% low fiber, 378 
34%, high fiber groups.  379 
 380 
Widespread inability amongst trial participants to recall specific costs associated with 381 
symptom management precluded formal analysis.   382 
383 
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Discussion  384 
This is the first randomized controlled trial (RCT) designed to test the efficacy of 385 
manipulating dietary fiber in patients receiving radical pelvic radiotherapy. Whilst no 386 
significant difference between groups was found in the primary outcome (change in 387 
IBDQ-B between baseline and nadir score), the results revealed a clinically significant 388 
difference in change score of 7.1 points (p=0.011) between the high fiber and habitual 389 
fiber groups, between start and end-RT, pointing to a clear benefit of increased fiber 390 
intake. The fact that at 1 year post-RT, the difference in score between these groups was 391 
8.5 points (p=0.004) indicating a longer term effect, fits with current concepts of 392 
radiotherapy toxicity that encompass the consequential effect (22), namely that severe 393 
acute toxicity predisposes to longer term severe toxicity. These differences between 394 
groups in the change in IBDQ-B score is equivalent to a ≥10% change, which has 395 
previously been defined as ‘meaningful clinical improvement’ (23). It should be noted 396 
that despite these results, we did not show a gradient of effect. IBDQ-B scores in the 397 
low fiber group were higher (less severe symptoms) at both time-points compared to the 398 
habitual fiber group, albeit not statistically significantly, indicating a possible benefit. 399 
The analysis of IBDQ (quality-of-life) scores revealed a similar pattern, with the high 400 
fiber group maintaining significantly improved scores compared to the habitual fiber 401 
group at end-RT (p=0.015) and at 1 year (p=<0.001).     402 
 403 
Conducting robust, large scale nutritional interventions requiring patients to adhere to 404 
targets and estimate intake are labour-intensive and far from straightforward. We set 405 
fiber targets based on the NSP content of foods to ensure compatibility with Dietary 406 
Reference Values in the UK at the time (24) and provided a study-specific booklet for 407 
patients to readily track their intake. Patients were coached to use this booklet rather 408 
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than food labels as their prime reference source and were given diaries in which to 409 
record daily self-estimated fiber consumption. In the UK, food labelling is based on the 410 
US Association of Official Analytical Chemists (AOAC) method of analysis which 411 
yields values 1.6 x NSP/100g food. Despite these potential pitfalls, we are confident in 412 
the validity of our findings since a clear differential in fiber intake was maintained 413 
between groups during the first and final week of treatment (p<0.001 both time-points). 414 
Most patients (85%) reported they found the booklets very easy to use and would 415 
recommend them to others wishing to track their fiber intake. We conclude from these 416 
results that patients in this setting can meet targets for fiber intake for the duration of 417 
their treatment period using dietary manipulation alone. Although, we acknowledge that 418 
achievement of compliance is a potentially complex process, for researchers and 419 
patients alike.     420 
 421 
Importantly, our findings challenge non-evidence based advice to restrict dietary fiber 422 
during radical pelvic radiotherapy. Analysis of stool frequency, form and number of 423 
days on which loose / watery stools was experienced showed no significant differences 424 
between groups in any of these characteristics. Thus, the premise that increased fiber 425 
exacerbates a tendency towards treatment-induced diarrhea appears to lack 426 
physiological foundation. On the contrary, optimal production of SCFA by bowel 427 
microbiota provided with ample fiber substrate would encourage sodium and water 428 
absorption (12) and thus help to counteract risk of loose or watery stool.  In addition to 429 
promoting water absorption, we hypothesized that increased fiber intake would enhance 430 
SCFA production which in turn would reduce inflammatory processes thereby 431 
mitigating symptoms as reflected in IBDQ-B scores. However, we found no difference 432 
between groups. This may be due to the small number of samples we obtained, the wide 433 
21 
 
 
inter-individual variations in stool SCFA concentrations that exist (25) and altered gut 434 
transit time during treatment (26, 27) which has a large effect on stool SCFA 435 
concentrations. Further studies are needed to explore our hypothesis. 436 
 437 
Our interventions had no adverse effect on body weight or total energy intake. The 438 
difference between the low and habitual fiber groups in change in BMI was of only 439 
borderline significance. Although all of these parameters decreased in all groups 440 
between baseline and end-RT, no significant differences between groups occurred. 441 
Within group analysis revealed no significant change in total energy or macronutrient 442 
intake in the high fiber group, a finding in keeping with recent research which 443 
challenges the long-held view that fiber leads to increased satiety and causes reduced 444 
energy intake (28, 29). However, significant within-group reductions in protein, fat and 445 
total energy intake occurred in the habitual and low fiber groups between baseline and 446 
end-RT. We cannot determine whether maintenance of total energy intake in the high 447 
fiber group contributed to their improved quality-of-life (IBDQ) scores or vice-versa 448 
although others have reported an association (30, 31).   449 
 450 
We recognize that there are a number of factors that could have confounded our results.  451 
First, there was considerable attrition at 1 year requiring imputation for ITT analysis. 452 
However, the habitual fiber group who reported the worst bowel symptoms in the acute 453 
setting also went on to experience the worst symptoms at 1 year post-RT which fits with 454 
previous research (5, 22). Secondly, treatment-related factors were balanced between 455 
groups at baseline. However, patient-related factors such as smoking history, 456 
inflammatory conditions and previous surgery all of which confer an adverse effect and 457 
in contrast, the use of anti-hypertensive medication and/or HMG CoA reductase 458 
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inhibitors which confer a protective effect (32) and could have influenced outcomes, 459 
were not captured. Thirdly, cytotoxic agents (anti-metabolite Capecitabine and 460 
alkylating agents Mitomycin C and Cisplatin) and/or non-cancer related medications, 461 
may cause gastrointestinal symptoms in their own right through inflammatory or other 462 
mechanisms and thus may exacerbate symptoms and overwhelm potentially protective 463 
nutritional agents.  464 
 465 
We conclude that individualized dietetic advice to follow a high fiber diet during pelvic 466 
radiotherapy was tolerable and resulted in reduced gastrointestinal toxicity both acutely 467 
at the end of radiotherapy and at one year after radiotherapy compared with habitual 468 
fiber intake. As we employed a physiological (dietary) intervention we are not able to 469 
determine whether any specific component or type of fiber confers most benefit (e.g. 470 
readily versus poorly fermentable) since all foods contain a diverse range of fiber 471 
substrates. We note that a low fiber diet also appeared to confer some benefit and may 472 
offer a degree of advantage via different mechanisms. However, we agree with others in 473 
that a critical objective for dietetic practice is that ineffective, unnecessary or restrictive 474 
practices that lack an evidence-base and yet place undue burden on patients are 475 
abandoned (31) and thus our recommendation is that advice to reduce fiber intake 476 
during pelvic radiotherapy be discarded.  477 
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Table 1 - Baseline characteristics of randomized patients 
  
Characteristic 
 
All 
Groups 
n=166 
Low  
fiber 
n=55 
Habitual 
fiber 
n=55 
High 
fiber 
n=56 
p value 
Age: years 
Median 
(min-max) 
62.5 
(26 – 91) 
62 
(26 – 91) 
63 
(35 – 88) 
64 
(28 – 87) 
0.959* 
Gender: n (%)  
Male 
Female 
 
70 (42) 
96 (58) 
 
26 (47) 
29 (53) 
 
23 (42) 
32 (58) 
 
21 (37) 
35 (63) 
0.580** 
Pelvic site: n (%) 
Gastrointestinal 
     Rectum 
     Colon 
     Anal 
 
Gynecological 
     Endometrial 
     Cervical 
     Vaginal 
     Vulval 
 
106 (64) 
77 (73) 
3 (2) 
26 (25) 
 
60 (36) 
36 (60) 
20 (33) 
3 (5) 
1 (2) 
 
36 (65) 
25 (69) 
2 (6) 
9 (25) 
 
19 (35) 
14 (74) 
5 (26) 
0 
0 
 
35 (64) 
26 (74) 
1 (3) 
8 (23) 
 
20 (36) 
13 (65) 
4 (20) 
2 (10) 
1 (5) 
 
35 (63) 
26 (74) 
0 (0) 
9 (26) 
 
21 (37) 
9 (43) 
11 (52) 
1 (5) 
0 
0.948** 
Concomitant CT: n 
(%)     
121 (72) 41 (75) 38 (69) 42 (75) 0.739** 
RT dose (Gy): 
Median 
(min-max) 
50.4 
(30.0 – 
70.0) 
50.4 
(30.0 – 
59.4) 
52.2 
(45.0 – 70.0) 
50.4 
(45.0 – 
69.6) 
0.398* 
Key: CT: chemotherapy; *Kruskal-Wallis’ test; **Chi-squared test  
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Table 2 - Summary of IBDQ-B and IBDQ scores between the three groups in the 
intention to treat population 
 
 
Low 
fiber 
n=53 
Habitual 
fiber 
n=54 
High  
fiber 
n=54 
ANOVA 
p value* 
Mean absolute IBDQ-B scores (standard deviation) 
   Baseline (start of RT) 63.9 (9.3) 64.1 (6.9) 61.7 (9.7) 0.273 
   End of RT  56.0 (10.7) 53.3 (13.2) 58.0 (10.2) 0.104 
   Nadir (lowest score) during RT 52.2 (10.5) 48.7 (12.8) 51.5 (11.6) 0.260 
   One year  post-RT 59.0 (10.9) 55.7 (11.5) 61.8 (11.8) 0.0241 
Mean change from baseline in IBDQ-B scores (standard deviation) 
   End RT -7.9 (11.3) -10.8 (13.5) -3.7 (12.8) 0.0142 
   Nadir (lowest score) during RT -11.8 (10.6) -15.5 (13.2) -10.2 (13.7) 0.093 
   One year  post-RT -4.9 (12.7) -8.4 (13.3) 0.1 (14.5) 0.0053 
Mean absolute IBDQ scores (standard deviation) 
 Start of RT (baseline) 196.3 (23.7) 194.4 (17.9) 191.7 (26.0) 0.566 
 End of RT  178.6 (26.6) 170.5 (33.4) 183.5 (28.1) 0.073 
 Nadir (lowest score) during RT 171.3 (28.0) 161.5 (33.6) 168.0 (32.0) 0.259 
 One year  post-RT 183.0 (26.8) 173.6 (32.0) 194.1 (23.1) 0.0014 
Mean change from baseline in IBDQ scores (standard deviation) 
 End RT -17.7 (26.2) -24.5 (32.0) -8.2 (30.2) 0.0185 
 Nadir (lowest score) during RT -25.9 (27.2) -33.4 (31.6) -23.7 (33.2) 0.203 
 One year  post-RT -13.23 (30.3) -21.4 (33.0) 2.14 (29.4) <0.0016 
 
* Analysis of Variance  
Negative values represent a fall in score (worsening symptoms) 
Bold type indicates significant at p<0.05 following ANOVA.  
Where values are statistically significant a Bonferroni post hoc correction was undertaken, 
superscripts indicate significant differences between groups as follows: 1: High fiber vs control 
group (p=0.019); 2: High fiber vs control group (p=0.011); 3: High fiber vs control group 
(p=0.004); 4: High fiber vs control group (p<0.001); 5: High fiber vs control group (p=0.015); 6: 
High fiber vs control group (p<0.001), high fiber vs low fiber group (p=0.030) 
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Table 3 - Summary of stool characteristics between groups in patients with 
completed stool charts 
 
 
Low  
fiber 
n=39 
Habitual 
fiber 
n=44 
High  
fiber 
n=42 
p value* 
Median stool frequency  / day (min-max) 
 Week 1 (start of RT) 
1.7  
(0.7 – 12.1) 
1.9  
(0.4 – 6.7) 
2.0 
(0.7 – 13.9) 0.797 
 Final week (end of RT)  2.7  
(0.6 – 11.0) 
3.0  
(0.3 – 13.5) 
2.3 
(0.9 – 13.8) 
0.636 
Median stool form  / day (min-max) 
 Week 1 (start of RT) 
5.0  
(2.4 – 6.6) 
4.7 
 (2.0 – 6.4) 
4.9  
(1.8 – 6.6) 0.630 
 Final week (end of RT)  
5.2  
(3.9 – 7.0) 
4.8  
(2.5 – 6.8) 
5.1 
 (3.0 – 6.6) 0.225 
Median no. of days / week with stool form of 6 or 7 (max-min) 
        Week 1 (start of RT) 
3 
(0 - 7 ) 
2 
(0 – 7) 
2  
(0 – 7) 0.627 
        Final week (end of RT)  
3.0 
(0 – 7) 
3.0 
(0 – 7) 
3.0 
(0 – 7) 0.934 
Median no. of days / week on which anti-diarrheal medication used (max-min) 
 Week 1 (start of RT) 
0 
(0 – 7) 
0 
(0 – 7) 
0 
(0 – 2) 0.713 
 Final week (end of RT) 
0 
(0 – 7) 
0 
(0 – 7) 
0 
(0 – 7) 0.515 
 
* Kruskal Wallis test  
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Table 4 - Summary of nutritional and anthropometric data between groups  
Nutritional data 
n (week 1) 
n (final week) 
n (change between week 1 & final week) 
Low fiber 
47 
41 
41 
Habitual 
51 
44 
44 
High fiber 
48 
43 
42 
ANOVA 
p value* 
Mean energy intake in kcals / day (standard deviation) 
Week 1 (start of RT) 1693 (415) 1883 (561) 1898 (524) 0.134 
Final week (end of RT) 1571 (496) 1715 (569) 1836 (453) 0.062 
Change -145 (381) - 170 (419) -110 (466) 0.805 
Mean fiber intake in g / day (standard deviation) 
Week 1 (start of RT) 10.2 (3.4) 13.6 (5.3) 17.1 (4.8) <0.0011 
Final week (end of RT) 8.9 (3.0) 12.2 (5.2) 15.7 (5.1) <0.0012 
Change -1.1 (2.8) -2.0 (3.7) -1.9 (4.5) 0.451 
Mean protein intake in g / day (standard deviation) 
Week 1 (start of RT) 70.9 (16.7) 73.4 (21.6) 78.3 (20.6) 0.187 
Final week (end of RT) 63.8 (19.8) 68.6 (24.5) 78.4 (22.7) <0.0123 
Change -8.5 (16.6) -7.4 (16.8) -1.9 (18.0) 0.176 
Mean fat intake in g / day (standard deviation) 
Week 1 (start of RT) 69.7 (25.0) 71.1 (27.0) 75.6 (26.7) 0.511 
Final week (end of RT) 63.2 (22.8) 65.9 (24.5) 73.0 (23.2) 0.144 
Change -8.2 (20.5) -8.3 (21.8) -4.4 (24.2) 0.654 
Mean carbohydrate (CHO) intake in g / day (standard deviation) 
Week 1 (start of RT) 186.3 (47.4) 207.3 (71.6) 216.9 (62.9) 0.051 
Final week (end of RT) 178.4 (66.1) 197.2 (72.8) 207.2 (57.7) 0.134 
Change -7.6 (50.6) -13.4 (48.3) -15.0 (54.9) 0.787 
Proportion (%) of participants ≥80% compliant with fiber target at final week  
Final week (end of RT) 34/41 (83%) 22/44 (50%) 27/43 (63%)  0.006** 
Anthropometric data 
n (week 1) 
n (final week) 
n (change between week 1& final week) 
Low fiber 
54 
49 
49 
Habitual 
55 
52 
52 
High fiber 
55 
50 
50 
ANOVA 
p value* 
Mean body weight in kg (standard deviation) 
Week 1 (start of RT) 78.3 (18.1) 81.0 (18.5) 77.5 (15.6) 0.559 
Final week (end of RT) 78.1 (17.9) 81.0 (18.0) 76.6 (16.6) 0.443 
Change -0.92 (5.0) -0.55 (2.1) 0.52 (2.2) 0.808 
Mean body mass index (BMI) in kg/m2 (standard deviation) 
Week 1 (start of RT) 27.8 (5.8) 28.4 (6.3) 28.0 (5.4) 0.880 
Final week (end of RT) 26.8 (5.0) 28.6 (6.4) 27.5 (5.4) 0.291 
Change -0.57 (1.0) 0.13 (0.9) -0.29 (0.9) 0.0374 
* Analysis of Variance; ** Chi-squared test; Change analysis using paired test; Bold type indicates 
significant at p<0.05;  Where values are statistically significant a Bonferroni post hoc correction was 
undertaken, key to superscripts as follows: 1: Habitual vs low fiber group (p=0.019), habitual vs high 
fiber group (p=0.001), low fiber vs high fiber group (p<0.001); 2: Habitual vs low fiber group (p=0.003), 
habitual vs high fiber group (p=0.001), low fiber vs high fiber group (p<0.001); 3: Habitual vs low fiber 
group (p=0.975), habitual vs high fiber group (p=0.134), low fiber vs high fiber group (p=0.011); 4. 
Habitual vs low fiber (p=0.058), habitual vs high fiber (p=1.000), low fiber vs high fiber (p=0.103). 
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Figure 1 - CONSORT style flowchart of patient accrual 
Key: NSP: Non-starch polysaccharide  
 
 
  
Randomized (n=166) 
Assessed for eligibility (n=882) 
 Habitual fiber group (control) 
(habitual fiber intake) 
(n=55) 
Suitable (n=583) 
Refused (n=417) 
   No dietary change (n=151) 
   Unable to cope (n=131) 
   No reason given (n=72) 
   Social circumstances (n=38) 
   Other reasons (n=25) 
  
 
Excluded (n=299) 
   Stoma (n=114) 
   Investigator logistics (n=58) 
   Plan change (n=32)   
   Co-morbidities (n=28) 
   Consultant decision (n=20) 
   Eligibility change (n=6) 
   Other reasons (n=41) 
Low fiber group  
(target ≤10 g/d NSP)  
(n=55) 
 
High fiber group 
(target ≥18 g/d NSP)  
(n=56) 
One year follow-up 
(chronic) 
Allocation 
Enrollment  
Completed (n=43) 
Lost to follow-up (n=6) 
Died (n=3) 
Completed (n=39) 
Lost to follow-up (n=9) 
Died (n=5) 
 
Completed (n=44) 
Lost to follow-up (n=9) 
Died (n=1) 
 
End of radiotherapy 
(acute) 
 
 
Completed (n=52)  
Withdrawn (n=3) 
 
 
Completed (n=53) 
Withdrawn (n=2)  
 
 
 
Completed (n=54) 
Withdrawn (n=2) 
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Supplemental Table 1 - Radiotherapy treatment protocols 
 
Pelvic site 
Total 
EBRT Dose 
(GY) 
Fractionation 
(no. attendances) 
Concomitant 
chemotherapy 
Treatment 
duration 
(weeks) 
Colorectal: Phase I 45 1.8 (25) 
Oral daily 
Capecitabine 
5 
Colorectal: Phase 
II 
(pre-operative) 
3.4 – 9.0 1.8 (3 - 5) 
Oral daily 
Capecitabine 
1 
Colorectal: Phase 
II 
(Post-operative) 
9.0 – 14.4 1.8 (5 - 9) 
Oral daily 
Capecitabine 
1 - 2 
Anus: Phase I  
(IMRT) 
30.6 1.8 (17) 
IV Mitomycin C 
with oral daily 
Capecitabine 
3 - 4 
Anus: Phase II 
(EBRT) 
19.8 1.8 (11) 
IV Mitomycin C 
with oral daily 
Capecitabine 
2 
Endometrium 45 1.8 (25) none 5 
Cervix 50.4 1.8 (28) 
IV Cisplatin  
(4 cycles) 
5 - 6 
Vulva, vagina, 
fallopian tube, 
ovary 
45 – 55.8 1.8 (25 -31) Individual review 5 - 6 
 
Key: IV: intravenous, IMRT: Intensity Modulated Radiotherapy, EBRT: External Beam (conformal) 
radiotherapy   
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Supplemental Table 2 - SCFA concentrations and change in concentration baseline 
and end of radiotherapy 
 
 
Time-point 
Control 
n=16 
Low fibre 
n=15 
High fibre 
n=10 
ANOVA 
p value 
SCFA concentration:  
µmol/g wet faeces 
    
Acetate  Baseline 8.65 (3.18) 9.64 (3.69) 11.93 (4.88) 0.116 
 End of RT 6.92 (2.48) 7.95 (3.51) 9.11 (3.62) 0.240 
Propionate  Baseline 2.33 (1.14) 2.47 (1.33) 3.13 (2.08) 0.395 
 End of RT 1.67 (0.86) 2.54 (1.36) 2.51 (1.20) 0.076 
Butyrate Baseline 1.54 (0.74) 1.49 (0.74) 2.20 (1.23) 0.113 
 End of RT 1.20 (0.66) 1.14 (0.73) 1.48 (1.14) 0.572 
Isobutyrate Baseline 0.30 (0.16) 0.38 (0.18) 0.48 (0.31) 0.114 
 End of RT 0.26 (0.12) 0.28 (0.10) 0.30 (0.14) 0.740 
Valerate Baseline 0.14 (0.06) 0.16 (0.08) 0.23 (0.13) 0.042* 
 End of RT 0.12 (0.50) 0.12 (0.07) 0.14 (0.08) 0.662 
Isovalerate Baseline 0.27 (0.12) 0.34 (0.16) 0.40 (0.25) 0.187 
 End of RT 0.25 (0.10) 0.35 (0.09) 0.30 (0.14) 0.975 
Total SCFA Baseline 13.2 (4.7) 14.5 (5.4) 18.4 (8.3) 0.110 
 End of RT 10.4 (3.9) 12.3 (5.2) 13.8 (5.7) 0.225 
Change from baseline to end of RT in 
SCFA concentration: µmol/g wet faeces 
    
Acetate  -1.73 (3.61) -1.68 (5.09) -2.82 (7.44) 0.846 
Propionate  -0.67 (1.29) 0.07 (1.41) -0.62 (1.95) 0.349 
Butyrate  -0.34 (0.57) -0.34 (0.74) -0.72 (1.89) 0.646 
Isobutyrate  -0.03 (0.14) -0.10 (0.20) -0.18 (0.29) 0.225 
Valerate  -0.02 (0.07) -0.05 (0.08) -0.09 (0.15) 0.222 
Isovalerate  -0.02 (0.11) -0.09 (0.17) -0.15 (0.21) 0.119 
Total SCFA  -2.8 (5.12) -2.19 (7.21) -4.58 (11.45) 0.750 
*significant: p<0.05 
 
 
 
 
